Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

NCT04266912 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Malignant Solid Neoplasm
Refractory Malignant Solid Neoplasm
Unresectable Malignant Solid Neoplasm

Interventions

DRUG: Avelumab
DRUG: Berzosertib

Sponsor

M.D. Anderson Cancer Center